NAFDAC’s Reinforcement Of Actions Against Fake, Substandard Drugs’ Dealers

Counterfeit, fake and substandard drugs have unimaginable devastating impact on individuals, families, the government, local pharmaceutical companies and investments, the economy and society at large.
In Nigeria, the menace of fake and substandard drugs is a significant public health concern, with alarming statistics by the National Agency for Food and Drug Administration and Control (NAFDAC) revealing that up to 70% of drugs in circulation are either counterfeit or substandard.
Approximately 500,000 people reportedly die annually from counterfeit drugs in sub-Saharan Africa, including Nigeria, underscoring the severe consequences the menace has on people’s health and quality of life of Nigerians, and more importantly, the investing public.
The activities of counterfeiters pose heavier risks for pharmaceutical companies, investors, and the huge investments they put into their businesses. Local pharmaceutical companies like Emzor Pharmaceutical Industries Limited have invested heavily in the construction of the largest state-of-the-art Active Pharmaceutical Ingredients (API) manufacturing plant in Sagamu, Ogun State.
The US$23m API pharmaceutical complex, known as Emzor Campus, is both a World Health Organization – (WHO) compliant and a cGMP – compliant factory occupying more than 60 Hectares of land and is the largest API facility in West Africa set up to combat the pervasive threat of malaria in Nigeria and sub Saharan Africa. Annually, it has the capacity to produce 400 million metric tonnes of quality APIs; and has already commenced the supply of millions of doses of medication ranging from antimalarials, pediatrics care, vitamins, and antiretrovirals to various international organisations through partnerships for public health intervention.
It has created thousands of direct and indirect jobs, making a significant impact on the delivery of quality healthcare services not only in Nigeria, but across the African continent, and boosting government revenues in taxes. The investment has received commendations from a wide spectrum of influencers, including members of the Senate Committee on Health, Federal Ministry of Health top officials, and NAFDAC leadership, describing it as a significant investment by Emzor Pharmaceutical and a significant contributor to Nigeria’s GDP growth.
Laudable as this investment by Emzor is, it is a classic example of investments by local investors in the pharmaceutical sector that is prone to the negative impact of counterfeiters, unless proactive steps are taken by the government to protect such investments and several others.
Fittingly, the recent enforcement action by NAFDAC to sanitise the nation’s pharmaceutical ecosystem with multiple raids on the illegal production factories and warehouses of drug counterfeiters in Idumota, Aba and Onitsha was a right step in the right direction. The raids led by the agency’s director-general, Prof. Mojisola Adeyeye, with support of top management officials and security operatives, led to the closure of over 3,000 fake drug outlets, confiscation of 24 truckloads of substandard drugs, ingredients and packages. At some other times, the agency has destroyed large consignments of seized fake and substandard drugs and court trial and jailing of perpetrators.
The enforcement actions are quite significant when one considers the economic burden counterfeiting poses on the health of Nigerians. Counterfeiting accounts for the rising cost of treatment because it decreases the efficacy of drugs. Many times, fake and substandard drugs cause drug reaction, complication for patients, elongated period of healing and hospital visits or hospitalisation. These put tremendous strain on people’s disposable income, particularly low-income earners.
NAFDAC’s increased regulatory actions were also significant because wrong administration of fake or substandard drugs to a patient can slow response to treatment and this exerts both financial and emotional burden on families and relations, and even health professionals that provide care. Significantly, long stay in hospital affects productivity.
The nation’s healthcare system at large is also adversely impacted by the presence of fake, substandard or expired drugs. Hospitals and health facilities get overwhelmed by the surge in patients seeking care as a result of people taking counterfeit medications.
Fake and counterfeit drugs have the potential to erode investments by local investors and be a disincentive for prospective investors. The presence of cheap counterfeit alternatives will affect the sale of genuine drugs manufactured and sold by regulatory-compliant pharmaceutical companies. This will cause a decline in sales, profits and impair their ability to operate sustainably and scale. Escalating decline in revenues of genuine product makers can lead to job cuts or staff layoffs, or even shutdown in the long-term.
Local investors like Emzor Pharmaceutical and others are contributing significantly to the growth and development of Nigeria’s GDP. The call on the National Assembly by NAFDAC for a review of current legislations and stiffer penalties, including making dealing in counterfeit drugs a capital offence, is worth considering.
To combat the menace of fake and substandard drugs headlong, it is essential that stakeholders work together to standardise the Nigerian’s pharmaceutical sector and protect investments in the nation’s strategic drug manufacturing sector. By working together, we can secure improved access to quality, affordable healthcare and quality of life for all Nigerians. NAFDAC’s efforts to ensure a more effective and efficient enforcement of regulations and standardisation of the sector are, therefore, commendable. The resilience and fighting spirit must not defrost.

